Graft Versus Host Disease

Graft Versus Host Disease (GVHD) is a complex condition that occurs when donor cells attack the recipient's body following an allogeneic stem cell or bone marrow transplant. Understanding GVHD, including its symptoms, causes, and treatments, is critical for patients and healthcare providers to manage this potentially life-threatening complication effectively.

---

What is Graft Versus Host Disease?

Graft-versus-host disease (GVHD) occurs when the immune cells from a donor (the graft) perceive the recipient's body (the host) as foreign and mount an immune response against it. GVHD is categorized into two main types: acute and chronic, each with distinct symptoms and treatment protocols.

---

Types of Graft Versus Host Disease (GVHD)

Graft-versus-host disease (GVHD) occurs when the transplanted immune cells attack the recipient's body, and it is primarily seen in stem cell or bone marrow transplants. There are two main types of GVHD, each with distinct characteristics:

Acute Graft Versus Host Disease (aGVHD)

This form tends to occur in the first 100 days following the transplant. It primarily affects the skin, liver, and digestive tract. There are no specific symptoms, but patients typically present with skin rashes, jaundice, and diarrhea. aGVHD typically ranges from mild to severe and requires urgent medical attention to avoid complications.

Chronic Graft Versus Host Disease (cGVHD)

This type of GVHD occurs in the months after the first 100 days and can last for months or years. Chronic GVHD can involve multiple organ systems, including the skin, eyes, lungs, liver and gut. Symptoms can include dry eyes, joint stiffness and lung problems. Chronic GVHD typically needs long-term management and treatment with immunosuppressive agents.

---

GVHD Stages

The Graft Versus Host Disease stages are used to classify the severity of the disease:

---

Graft Versus Host Disease Symptoms​

Common symptoms of Graft Versus Host Disease include:

Acute graft versus host disease (aGvHD) symptoms

Chronic Graft Versus Host Disease (cGvHD) Symptoms

---

Graft Versus Host Disease Causes

GVHD is primarily caused by the immune response of the donor's T cells against the recipient's tissues. Several factors contribute to the likelihood and severity of GVHD:

---

Risk Factors for Graft Versus Host Disease

Several risk factors for graft versus host disease can increase the likelihood of developing this condition, including:

---

Graft Versus Host Disease Diagnosis

The diagnosis of GVHD involves a combination of clinical assessment, laboratory tests, and biopsies. Early detection and accurate diagnosis are crucial for effective management.

Clinical Assessment

Healthcare providers will conduct a thorough examination, noting symptoms and their onset. A detailed patient history, including the type of transplant and donor information, is essential.

Laboratory Tests

Blood tests can reveal elevated liver enzymes, bilirubin levels, and other markers indicative of GVHD. If gastrointestinal symptoms are present, stool tests may be performed.

Biopsies

Biopsies of affected tissues, such as skin, liver, or gastrointestinal tract, can confirm the diagnosis. Histopathological examination helps to identify characteristic changes associated with GVHD.

---

Graft Versus Host Disease Treatment

Treatment strategies for GVHD aim to suppress the donor immune cells' attack on the recipient's body while preserving the graft's beneficial effects, such as graft-versus-leukemia (GVL) activity.

Corticosteroids

Corticosteroids, such as prednisone, are the cornerstone of GVHD treatment. They suppress the immune response and reduce inflammation. However, long-term use can have significant side effects, including increased infection risk, osteoporosis, and hyperglycemia.

Calcineurin Inhibitors

Calcineurin inhibitors, such as cyclosporine and tacrolimus, are often used in conjunction with corticosteroids. They inhibit T-cell activation and proliferation, helping to control GVHD symptoms.

Extracorporeal Photopheresis (ECP)

ECP involves collecting the patient's blood, treating it with a photosensitizing agent, and exposing it to ultraviolet light before re-infusing it. This process modulates the immune response and can be effective in managing chronic GVHD.

Monoclonal Antibodies

Monoclonal antibodies, such as rituximab and infliximab, target specific components of the immune system. They can treat steroid-refractory GVHD and other complications.

Emerging Therapies

Research into new treatments for GVHD is ongoing. Some promising areas include:

Janus Kinase (JAK) Inhibitors

JAK inhibitors, such as ruxolitinib, target specific pathways involved in the immune response. Early studies suggest they may be effective in treating both acute and chronic GVHD.

Mesenchymal Stem Cells (MSCs)

MSCs have immunomodulatory properties and can promote tissue repair. They are being investigated as a potential treatment for severe GVHD.

---

Preventing Graft Versus Host Disease

Preventing GVHD involves careful donor selection, conditioning regimens, and prophylactic treatments.

Donor Selection

Choosing a donor with a close HLA match significantly reduces the risk of GVHD. Sibling donors with a perfect match are preferred, but unrelated donors can also be considered with appropriate matching.

Conditioning Regimens

The conditioning regimen, which includes chemotherapy and/or radiation, helps to prepare the recipient's body for the transplant. Adjusting the intensity of the regimen can influence the likelihood of GVHD.

Prophylactic Treatments

Prophylactic treatments, such as immunosuppressive drugs, are administered before and after the transplant to reduce the risk of GVHD. Common agents include methotrexate and mycophenolate mofetil.

---

Living with Graft Versus Host Disease

Managing GVHD is a long-term process that requires ongoing medical care and lifestyle adjustments.

Medical Follow-Up

Regular follow-up appointments with healthcare providers are essential to monitor symptoms, adjust treatments, and manage side effects. Early intervention can prevent complications and improve outcomes.

Supportive Care

Supportive care, including physical therapy, nutritional support, and psychological counseling, can help patients cope with the physical and emotional challenges of GVHD.

Patient Education

Educating patients and caregivers about GVHD, its symptoms, and treatment options empowers them to participate actively in their care. Providing resources and support groups can also enhance their quality of life.